NASDAQ:BSTC - BioSpecifics Technologies Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$65.08 +0.07 (+0.11 %)
(As of 03/26/2019 03:58 AM ET)
Previous Close$65.01
Today's Range$63.01 - $65.52
52-Week Range$40.54 - $73.31
Volume52,255 shs
Average Volume45,569 shs
Market Capitalization$473.65 million
P/E Ratio38.28
Dividend YieldN/A
Beta1.29
BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brand names. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.

Receive BSTC News and Ratings via Email

Sign-up to receive the latest news and ratings for BSTC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BSTC
CUSIP09093110
Phone516-593-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$27.44 million
Cash Flow$2.0408 per share
Book Value$9.39 per share

Profitability

Net Income$11.32 million

Miscellaneous

Employees5
Market Cap$473.65 million
Next Earnings Date3/27/2019 (Estimated)
OptionableNot Optionable

BioSpecifics Technologies (NASDAQ:BSTC) Frequently Asked Questions

What is BioSpecifics Technologies' stock symbol?

BioSpecifics Technologies trades on the NASDAQ under the ticker symbol "BSTC."

How were BioSpecifics Technologies' earnings last quarter?

BioSpecifics Technologies Corp. (NASDAQ:BSTC) announced its quarterly earnings results on Friday, November, 9th. The biopharmaceutical company reported $0.69 EPS for the quarter, topping analysts' consensus estimates of $0.55 by $0.14. The biopharmaceutical company earned $8.17 million during the quarter, compared to analysts' expectations of $7.19 million. BioSpecifics Technologies had a net margin of 54.96% and a return on equity of 20.81%. View BioSpecifics Technologies' Earnings History.

When is BioSpecifics Technologies' next earnings date?

BioSpecifics Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, March 27th 2019. View Earnings Estimates for BioSpecifics Technologies.

What price target have analysts set for BSTC?

1 Wall Street analysts have issued 1 year target prices for BioSpecifics Technologies' shares. Their forecasts range from $85.00 to $85.00. On average, they expect BioSpecifics Technologies' share price to reach $85.00 in the next twelve months. This suggests a possible upside of 30.6% from the stock's current price. View Analyst Price Targets for BioSpecifics Technologies.

What is the consensus analysts' recommendation for BioSpecifics Technologies?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioSpecifics Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioSpecifics Technologies.

Has BioSpecifics Technologies been receiving favorable news coverage?

News coverage about BSTC stock has been trending neutral this week, InfoTrie reports. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BioSpecifics Technologies earned a news impact score of 0.2 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 8.0 out of 10, indicating that recent news coverage is very likely to have an effect on the stock's share price in the next several days.

Who are some of BioSpecifics Technologies' key competitors?

What other stocks do shareholders of BioSpecifics Technologies own?

Who are BioSpecifics Technologies' key executives?

BioSpecifics Technologies' management team includes the folowing people:
  • Mr. Thomas L. Wegman, CEO, Pres, Principal Financial & Accounting Officer and Director (Age 64)
  • Dr. Ronald Law, Sr. VP of Bus. Devel. (Age 66)
  • Carl A. Valenstein, Corp. Sec.

Who are BioSpecifics Technologies' major shareholders?

BioSpecifics Technologies' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.06%), Dimensional Fund Advisors LP (3.97%), Dimensional Fund Advisors LP (3.97%), Stonepine Capital Management LLC (2.99%), Acadian Asset Management LLC (2.02%) and Elk Creek Partners LLC (1.45%). Company insiders that own BioSpecifics Technologies stock include Mark N Wegman, Of Edwin H Wegman Estate, Paul Gitman, Thomas Wegman and Toby Wegman. View Institutional Ownership Trends for BioSpecifics Technologies.

Which institutional investors are selling BioSpecifics Technologies stock?

BSTC stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Eagle Asset Management Inc., Thomson Horstmann & Bryant Inc., Elk Creek Partners LLC, Royce & Associates LP, First Manhattan Co., D. E. Shaw & Co. Inc. and Strs Ohio. Company insiders that have sold BioSpecifics Technologies company stock in the last year include Mark N Wegman, Of Edwin H Wegman Estate, Paul Gitman, Thomas Wegman and Toby Wegman. View Insider Buying and Selling for BioSpecifics Technologies.

Which institutional investors are buying BioSpecifics Technologies stock?

BSTC stock was purchased by a variety of institutional investors in the last quarter, including American Century Companies Inc., BlackRock Inc., Assenagon Asset Management S.A., Millennium Management LLC, Northpointe Capital LLC, ClariVest Asset Management LLC, Acadian Asset Management LLC and Dupont Capital Management Corp. View Insider Buying and Selling for BioSpecifics Technologies.

How do I buy shares of BioSpecifics Technologies?

Shares of BSTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioSpecifics Technologies' stock price today?

One share of BSTC stock can currently be purchased for approximately $65.08.

How big of a company is BioSpecifics Technologies?

BioSpecifics Technologies has a market capitalization of $473.65 million and generates $27.44 million in revenue each year. The biopharmaceutical company earns $11.32 million in net income (profit) each year or $1.70 on an earnings per share basis. BioSpecifics Technologies employs 5 workers across the globe.

What is BioSpecifics Technologies' official website?

The official website for BioSpecifics Technologies is http://www.biospecifics.com.

How can I contact BioSpecifics Technologies?

BioSpecifics Technologies' mailing address is 35 Wilbur Street, Lynbrook NY, 11563. The biopharmaceutical company can be reached via phone at 516-593-7000 or via email at [email protected]


MarketBeat Community Rating for BioSpecifics Technologies (NASDAQ BSTC)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  211 (Vote Outperform)
Underperform Votes:  148 (Vote Underperform)
Total Votes:  359
MarketBeat's community ratings are surveys of what our community members think about BioSpecifics Technologies and other stocks. Vote "Outperform" if you believe BSTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/26/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel